Vaccines 2020: World Market Analysis, Players, Trends

Vaccines 2020: World Market Analysis, Players, Trends

This report examines the market for these vaccines used to prevent various types of disease, and provides market modeling by disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines for diseases that are not currently vaccine-preventable, such as addiction and malaria. The report also discusses trends and looks at what vaccine companies have done and are planning. It also covers the COVID-19 vaccine market landscape, development progress and estimated market opportunity as of October 2020.

Because of the large number of deadly diseases that have been virtually eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements during the 20th century. As a result of widespread public vaccination, vaccine-preventable diseases and their resulting deaths are now rare in the developed nations and declining worldwide. Immunizations have eradicated smallpox; eliminated poliomyelitis in the Americas; and controlled measles, rubella, tetanus, diphtheria,

As part of its offering this report involves the following data points and others:

• Influenza Vaccine Global Market, 2020-2025
• US, European, and ROW Vaccine Markets by Type (Hepatitis, Combinations, Meningitis, Pneumococcal, Rotavirus, Influenza, HPV, Shingles, Others)
• Major Manufacturers’ Shares of the Global Vaccine Market, 2020
• Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, HPV, Others) 2020–2025
• Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020–2025
• Selected Pediatric Vaccines in Development, 2020
• Selected Adult Vaccines in Development, 2020
• COVID-19 Vaccine Developments
• COVID-19 Vaccine Potential Market Estimate, High Case and Low Case
• Development of new vaccines is ongoing. Generally speaking, vaccine clinical development in the world’s major markets follows a similar pathway as drugs and other biologics. A sponsor who wishes to begin clinical trials with a vaccine must first obtain permission to conduct clinical studies. In the U.S., this requires the submission of an Investigational New Drug (IND) application to the FDA.

“mitigating against growth will be continuing concerns about vaccine safety and refusal to immunize.”

The IND describes the vaccine, its method of manufacture, and quality control tests for release. Also included is information about the vaccine’s safety and ability to elicit a protective immune response (immunogenicity) in animal testing as well as the proposed clinical protocol for studies in humans. Kalorama’s report tracks development of vaccines, including those for COVID-19.

The report as well reviews the history and lines of business, strategic alliances, vaccine products, and financial information of market leaders such as GlaxoSmithKline, Merck, Pfizer, and Sanofi Pasteur.

COMPANY COVERAGE

Companies Covered in the Report Include:
ADVAXIS
BAVARIAN NORDIC, A/S
BHARAT BIOTECH INTERNATIONAL
CSL LIMITED/SEQIRUS
EMERGENT BIOSOLUTIONS
GLAXOSMITHKLINE
HAWAII BIOTECH
IMMUNE RESPONSE BIOPHARMA
INOVIO PHARMACEUTICALS
JOHNSON & JOHNSON/CRUCELL/JANSSEN
MEDICAGO
MERCK & CO
MITSUBISHI TANABE PHARMA CORPORATION
MODERNA
NOVAVAX
PFIZER
SANOFI PASTEUR
SERUM INSTITUTE
SOLIGENIX
TAKEDA PHARMACEUTICAL CO
VALNEVA SE